Wall Street brokerages expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to announce $2.26 million in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.50 million to $3.28 million. Tetraphase Pharmaceuticals posted sales of $1.09 million during the same quarter last year, which suggests a positive year-over-year growth rate of 107.3%. The business is scheduled to report its next earnings results on Wednesday, March 14th.

On average, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $2.26 million for the current fiscal year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts anticipate that the company will post sales of $6.90 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm’s revenue was up 355.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.58) EPS.

A number of research analysts recently weighed in on TTPH shares. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price objective (up from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Wednesday, August 9th. Finally, BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $15.15.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/09/tetraphase-pharmaceuticals-inc-ttph-expected-to-announce-quarterly-sales-of-2-26-million.html.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.15 during mid-day trading on Thursday, hitting $6.15. The company had a trading volume of 127,381 shares, compared to its average volume of 440,060. Tetraphase Pharmaceuticals has a 1-year low of $3.39 and a 1-year high of $9.93.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $5.86, for a total value of $41,928.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 33,405 shares of company stock valued at $199,691. 5.50% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Tetraphase Pharmaceuticals in the third quarter worth $107,000. Brighton Jones LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at $108,000. UBS Group AG grew its position in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares in the last quarter. AXA purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $132,000. Finally, Jane Street Group LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the first quarter valued at $181,000. 42.68% of the stock is owned by hedge funds and other institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.